genet
immun
one
import
find
provid
multifacet
immunolog
respons
infecti
diseas
advent
rdna
technolog
possibl
construct
vector
immunolog
activ
gene
specif
pathogen
nevertheless
sitespecif
deliveri
construct
genet
materi
import
contributori
factor
elicit
specif
cellular
humor
immun
respons
nanotechnolog
demonstr
immens
potenti
sitespecif
deliveri
biomolecul
sever
polymer
lipid
nanocarri
util
deliveri
genet
materi
system
seem
better
compat
low
toxic
econom
capabl
deliv
biomolecul
intracellular
site
better
express
desir
antigen
surfac
engin
nanocarri
target
approach
abil
offer
better
present
antigen
materi
immunolog
cell
chapter
give
overview
exist
emerg
nanotechnolog
approach
deliveri
genet
materi
vaccin
develop
offer
attract
costeffect
prevent
approach
deadli
diseas
new
advanc
immunolog
molecular
biolog
biotechnolog
low
develop
uniqu
safe
effect
dread
diseas
like
hiv
cancer
hepat
tuberculosi
etc
tabl
genet
immun
hold
potenti
discov
new
vaccin
may
effici
vaccin
deliveri
system
earli
dna
vaccin
burst
scientif
limelight
tang
johnston
describ
deliveri
dna
use
gene
gun
mice
skin
felt
could
use
techniqu
gener
antibodi
respons
specif
transgen
product
tang
et
al
annual
vaccin
meet
cold
spring
harbor
laboratori
report
drive
humor
cellular
immun
respons
pathogen
tumor
antigen
vivo
use
dna
vector
merck
pharmaceut
compani
report
develop
immun
respons
influenza
viru
antigen
mice
inject
nake
plasmid
intramuscularli
ulmer
et
al
similarli
robinson
prove
abil
dna
plasmid
influenza
viru
antigen
fynan
et
al
capabl
plasmid
carri
hiv
antigen
tumor
antigen
gener
immun
respons
protect
tumor
mice
describ
wang
et
al
importantli
dna
vaccin
affect
humor
well
cellular
immun
use
dna
approach
also
promis
overcom
safeti
concern
associ
live
vaccinestheir
revers
risk
potenti
spread
unintend
individu
avoid
risk
link
manufactur
kill
vaccin
ruprecht
vaccin
gener
compos
whole
organismeith
live
weaken
kill
form
firstgener
vaccin
live
attenu
organ
smallpox
polio
vaccin
abl
induc
killer
tcell
c
respons
helper
tcell
h
respons
antibodi
immun
fig
firstgener
vaccin
provid
maximum
protect
associ
risk
attenu
form
pathogen
revert
danger
form
may
still
abl
caus
diseas
especi
immun
compromis
vaccin
recipi
eg
aid
patient
kill
vaccin
gener
specif
killer
tcell
respons
effect
limit
diseas
cellular
respons
essenti
alarcon
et
al
reason
initi
research
secondgener
vaccin
secondgener
vaccin
subunit
vaccin
consist
defin
protein
antigen
tetanu
diphtheria
toxoid
recombin
protein
compon
hepat
b
surfac
antigen
surfac
protein
influenza
vaccin
abl
gener
th
antibodi
respons
killer
tcell
respons
reason
restrict
util
vaccin
limit
number
diseas
today
era
genet
immun
nextgener
vaccin
third
gener
seem
highli
effect
till
date
strategi
base
upon
improv
gene
optim
improv
rna
structur
design
novel
formul
immun
adjuv
effect
deliveri
approach
alarcon
et
al
robinson
pertmer
cellular
level
introduct
nanotechnolog
develop
nanocarrierbas
vaccin
provid
effect
immun
better
target
trigger
antibodi
respons
order
induc
effect
protect
immun
vaccin
requir
boost
agent
call
adjuv
adjuv
deliveri
vehicl
shown
protect
antigen
degrad
current
trend
toward
mani
effort
develop
novel
adjuv
carrier
persist
system
microand
nanoscal
immun
tradit
vaccin
requir
administr
live
attenu
viru
kill
organ
wherea
dna
vaccin
construct
encod
specif
antigen
determin
dna
vaccin
highli
flexibl
stabl
easili
store
manufactur
larg
scale
encod
sever
type
gene
includ
viral
bacteri
antigen
immunolog
biolog
protein
gengoux
leclerc
kutzler
weiner
mani
potenti
advantag
dna
vaccin
summar
tabl
gene
interest
antigen
determin
insert
recombin
vector
like
multipl
clone
region
plasmid
enzymat
synthet
pcr
deliv
inocul
site
one
sever
deliveri
method
like
physic
gene
gun
electropor
viral
virosom
nonvir
liposom
microspher
nanospher
either
skin
intraderm
subcutaneum
muscl
mechan
dna
vaccin
produc
antigenspecif
immun
vivo
intens
investig
ideal
model
present
fig
figur
repres
overview
mechan
plasmid
uptak
proteinac
antigen
express
either
somat
cell
eg
myocyt
keratinocyt
site
inject
resid
antigenpres
cell
apc
immatur
dendrit
cell
mechan
includ
direct
target
dendrit
cell
langerhan
cell
ie
skin
dendrit
cell
gene
gun
administr
plasmid
dna
involv
highspe
shoot
gold
microbead
coat
plasmid
dna
upper
layer
skin
b
crossprim
like
intramuscular
inject
parenter
inject
somat
cell
mention
primarili
express
protein
encod
success
dna
vaccin
concern
improv
immunogen
safeti
therefor
urgent
need
develop
potent
safe
adjuv
deliveri
system
use
new
gener
vaccin
shown
fig
sever
way
antigen
express
immunogen
improv
dna
vaccin
platform
lot
step
undertaken
modifi
immunogen
safeti
dna
vaccin
fig
promot
import
compon
plasmid
drive
high
level
express
gene
interest
variou
promot
util
improv
express
vaccin
gene
human
cytomegaloviru
cmv
promot
extens
use
high
level
protein
express
mammalian
cell
boshart
et
al
howev
drawback
associ
cmv
promot
like
chromatin
condens
histon
deacetylas
recent
histon
deacetylas
inhibitor
supplement
cmv
promoterbas
plasmid
shown
increas
express
dna
vaccin
antigen
lai
et
al
immediateearli
promot
one
also
demonstr
better
gene
express
insect
cell
compar
cmv
promot
et
al
porcin
circoviru
type
capsid
gene
promot
enhanc
antigen
express
immunogen
plasmid
vaccin
tanzer
et
al
regul
transcript
termin
key
element
control
gene
express
within
framework
singl
transcript
promot
barr
et
al
one
effect
way
increas
protein
product
use
codon
optim
adopt
speciesspecif
codon
chang
gustafsson
et
al
plasmid
backbon
optim
also
import
contributori
factor
dna
vaccin
replac
polyadenyl
splice
signal
paec
plasmid
vector
synthet
intron
synthet
rabbit
beta
globinbas
terminationpolyadenyl
sequenc
cpg
motif
enhanc
cellmedi
ifngammasecret
activ
rna
polymeras
ii
depend
cytomegaloviru
immedi
earli
cmv
ie
enhancerpromot
promot
psmcta
pshcta
util
enhanc
express
antigen
substanc
yu
et
al
viral
vector
tool
commonli
use
molecular
biologist
deliv
genet
materi
cell
viral
vector
vaccin
use
live
virus
carri
dna
human
cell
consist
nonrepl
viru
contain
defin
genet
fig
factor
affect
immunogen
dna
vaccin
materi
pathogen
immun
desir
virus
evolv
special
molecular
mechan
effici
transport
genom
insid
cell
infect
viral
vector
vaccin
carri
dna
host
cell
product
antigen
protein
tailor
stimul
rang
immun
respons
includ
antibodi
helper
cell
cell
cytotox
lymphocyt
ctl
cell
mediat
immun
draper
heeney
retrovirus
parvovirus
adenovirus
lentivirus
adenoassoci
virus
herp
simplex
viru
investig
abil
transfer
dna
gene
express
high
transfect
effici
tissu
kidney
heart
muscl
eye
ovari
achiev
use
viral
vector
advantag
viralvector
vaccin
includ
eas
product
good
safeti
profil
abil
potenti
strong
immun
respons
infect
broad
spectrum
cell
type
trigger
tlymphocyt
activ
potenti
nasal
epicutan
deliveri
mucos
immun
chamberlain
galimi
verma
lien
lai
martin
et
al
mctaggart
alrubeai
wolf
jenkin
recombin
retrovirus
abil
integr
host
genom
stabl
fashion
contain
revers
transcriptas
allow
integr
host
genom
kb
typic
maximum
length
allow
dna
insert
replicationdefect
viral
vector
lentivirus
subclass
retrovirus
uniqu
featur
lentivirus
abil
integr
genom
nondivid
cell
wherea
retrovirus
infect
divid
cell
viru
enter
cell
viral
genom
form
rna
revers
transcrib
produc
dna
insert
genom
viral
integras
cattoglio
et
al
primari
applic
gene
therapi
vaccin
limit
use
basic
research
due
integr
genom
replic
cell
divis
respiratori
gastrointestin
eye
infect
commonli
caus
human
contact
adenovirus
adenoassoci
viru
aav
small
viru
infect
divid
nondivid
cell
human
primat
speci
may
incorpor
genom
host
cell
caus
mild
immun
respons
featur
make
aav
attract
candid
creat
viral
vector
gene
therapi
goff
berg
nowaday
incorpor
molecular
adjuv
main
strategi
melior
vaccin
coinject
plasmid
encod
cytokin
chemokin
costimulatori
molecul
like
death
receptor
growth
factor
adhes
molecul
tollreceptor
ligand
use
individu
combin
maxim
substanti
effect
immun
respons
clinic
prophylact
therapeut
studi
plasmidencod
antigen
exampl
boost
humor
cellular
respons
antigen
coadminist
synthet
oligodeoxynucleotid
contain
unmethyl
cpg
motif
mice
higgin
et
al
recent
immunomodul
base
target
antigenpres
cell
apc
majorli
macrophag
use
macrosialin
promot
immun
respons
construct
plasmid
express
jev
envelop
e
protein
control
aforesaid
promot
cytomegaloviru
cmv
immedi
earli
promot
jev
induc
compar
immun
comparison
ubiquit
promot
construct
ahsan
gore
nk
group
member
also
report
potentactiv
receptor
express
cell
innat
adapt
immun
system
recombin
mous
cmv
express
highaffin
ligand
shown
better
express
profound
viru
attenu
vivo
could
power
develop
immunogen
hcmv
vaccin
slavuljica
et
al
vivo
dendrit
cell
dc
target
attract
approach
potenti
advantag
vaccin
efficaci
cost
avail
genet
target
dcspecif
activ
transcript
factor
dc
potenti
vaccineinduc
prophylact
therapeut
antitumor
immun
multipl
tumor
model
tian
et
al
recent
heterodimer
antigenpres
cell
target
multireceptor
ligand
approach
implement
access
potenti
one
apcspecif
target
unit
antigen
molecul
result
reveal
heterodimer
barnasebarstar
vaccin
molecul
potent
provid
flexibl
platform
develop
novel
dna
vaccin
increas
potenc
spang
et
al
mechan
adjuv
action
discuss
vaccin
adjuv
increas
potenc
immun
respons
small
antigen
weak
synthet
recombin
peptid
immunolog
immatur
immunosuppress
senesc
individu
improv
immun
respons
stronger
antigen
respect
speed
vigor
persist
exampl
aluminum
adjuv
adsorb
dtp
elicit
earli
higher
antibodi
respons
primari
immun
unadjuv
prepar
vaccin
adjuv
modul
antibodi
avid
specif
quantiti
isotyp
subclass
epitop
complex
immunogen
target
antigen
cellsurfac
receptor
apc
format
multimolecular
aggreg
direct
antigen
present
direct
peptid
exchang
surfac
mhc
molecul
mhc
class
mhc
class
ii
pathway
mean
fusion
disrupt
cell
membran
newman
powel
import
characterist
adjuv
vaccin
efficaci
aqueou
vaccin
unfortun
absolut
safeti
adjuv
vaccin
vaccin
guarante
real
theoret
risk
administ
vaccin
adjuv
local
acut
chronic
inflamm
pain
abscess
persist
nodul
ulcer
fever
hypersensit
anaphylaxi
chemic
toxic
tissu
organ
autoimmun
arthriti
amyloidosi
anterior
uveiti
glomerulonephr
meningoenceph
immun
suppress
oral
toler
carcinogenesi
teratogenesi
abortogenesi
spread
live
vector
vaccin
environ
edelman
tacket
bussier
et
al
goldenth
et
al
must
safe
includ
freedom
side
effect
afford
stabl
biodegrad
easili
remov
bodi
adjuv
effect
efficaci
immunogen
achiev
use
fewer
dose
andor
lower
concentr
antigen
elicit
vigor
protect
therapeut
immun
respons
combin
antigen
antigen
administ
alon
must
defin
chemic
biolog
lottolot
variat
manufactur
product
freund
adjuv
solut
antigen
emulsifi
miner
oil
use
immunopotenti
booster
freund
complet
adjuv
fca
compos
inactiv
dri
mycobacteria
wherea
incomplet
form
fia
lack
mycobacteri
compon
although
fca
prove
potent
induc
cellmedi
immun
abil
boost
humor
immun
respons
associ
advers
side
effect
like
steril
abscess
granuloma
muscl
indur
plasma
cell
neoplasia
ascit
amyloidosi
limit
util
modifi
version
fca
known
freund
incomplet
adjuv
fia
antigen
administ
waterinoil
wo
emuls
without
mycobacteri
compon
consist
mixtur
miner
oil
drakeol
bayol
f
marcol
vv
emulsifi
mannid
monool
vv
equal
volum
aqueou
solut
antigen
mechan
freund
adjuv
allow
gradual
continu
releas
antigen
establish
repositori
antigencontain
locu
site
inject
interact
mononuclear
cell
phagocyt
cell
antigen
present
cell
etc
fia
includ
veterinari
vaccin
rabi
hog
cholera
canin
hepat
freund
et
al
fastier
hansen
ott
well
human
vaccin
tetanu
toxoid
influenza
vaccin
salk
et
al
gener
fia
fca
inde
effici
rais
high
antibodi
titer
induc
cytotox
lymphocyt
ctl
use
prime
immun
morozova
et
al
investig
develop
inflammatori
respons
rat
myocardium
immun
rat
singl
subcutan
inject
cardiac
myosin
ugkg
incomplet
freund
adjuv
ifa
gjess
et
al
limit
studi
conduct
signifi
util
freund
adjuv
dna
vaccin
demonstr
plasmid
suspend
ifa
significantli
enhanc
type
cellular
humor
immun
respons
hbsag
luo
et
al
aluminum
compound
aluminum
phosphat
alpo
aluminum
hydroxid
al
oh
alum
precipit
vaccin
current
commonli
use
adjuv
human
veterinari
vaccin
owe
good
track
record
safeti
low
cost
adjuvant
varieti
antigen
gupta
et
al
gupta
siber
howev
aluminum
adjuv
certain
limit
local
reaction
site
inject
ige
antibodi
respons
augment
ineffect
antigen
inabl
supplement
cellmedi
immun
respons
two
method
use
prepar
vaccin
toxoid
aluminum
compoundsin
situ
precipit
aluminum
compound
presenc
antigen
adsorpt
antigen
onto
preform
aluminum
gel
april
wardlaw
holt
et
al
hem
white
gupta
mechan
adjuvant
aluminum
compound
includ
format
depot
effici
uptak
antigenpres
cell
stimul
immun
compet
cell
bodi
induct
eosinophilia
activ
macrophag
complement
recent
adjuvant
alum
report
due
cell
death
subsequ
releas
host
cell
dna
act
potent
endogen
immunostimulatori
signalmedi
alum
adjuv
activ
marich
et
al
gupta
et
al
show
diphtheria
toxoid
adsorb
aluminum
phosphat
induc
signific
antibodi
level
rabbit
previous
manam
et
al
report
aluminum
phosphat
adjuv
shown
effect
tissu
distribut
integr
frequenc
deliveri
genet
materi
manam
et
al
similarli
liang
et
al
show
similar
result
indic
increas
hbsag
express
plasmid
mix
aluminum
phosphat
howev
demonstr
better
antibodi
titer
intramuscular
immun
balbc
mice
mix
aluminum
phosphat
adjuv
studi
reveal
aluminum
phosphat
potenti
dna
vaccin
liang
et
al
recent
yu
et
al
demonstr
role
aluminum
adjuv
dna
vaccin
botulinum
neurotoxin
bont
shown
induc
protect
humor
immun
respons
yu
et
al
combin
use
alum
adjuv
dna
immun
also
demonstr
signific
chang
surviv
rate
vaccin
anim
toxoplasma
gondii
khosroshahi
et
al
cytokin
group
secret
lowmolecular
weight
protein
cell
innat
adapt
immun
major
role
celltocel
commun
cytokin
play
import
role
induct
immun
respons
process
present
antigen
numer
cytokin
includ
granulocytemacrophag
coloni
stimul
factor
gmcsf
shown
significantli
modul
inflammatori
process
given
system
local
administr
increas
local
express
major
histocompat
mhc
class
ii
antigen
enhanc
skin
antigen
reactiv
high
bolu
dose
caus
hypotens
exacerb
underli
autoimmun
diseas
induc
vascular
leak
syndrom
studi
reveal
exogen
could
valuabl
adjunct
treatment
immunodefici
viru
hiv
infect
human
decreas
frequenc
apoptot
peripher
blood
mononuclear
cell
pmbc
may
contribut
increas
circul
cd
cell
also
induc
bcell
activ
antibodi
synthesi
vitro
cordiali
fei
et
al
among
variou
improv
strategi
incorpor
cytokineexpress
plasmid
molecular
adjuv
wide
studi
past
year
yet
still
without
signific
clinic
applic
chapter
review
recent
progress
coapplic
cytokineencod
gene
use
enhanc
direct
immunogen
well
discuss
therapeut
potenti
futur
applic
coadministr
proinflammatori
agent
variou
interleukin
tumor
necrosi
factor
gmcsf
plu
cytokin
increas
antibodi
respons
wherea
proinflammatori
agent
cytokin
decreas
humor
respons
increas
cytotox
respons
import
viral
protect
exampl
costimulatori
molecul
like
also
sometim
use
mpl
monophosphoryl
lipid
immunostimul
deriv
lipopolysaccharid
lp
salmonella
minnesota
import
characterist
mpl
adjuv
activ
enhanc
gener
specif
immun
without
directli
associ
antigen
choic
mpl
adjuv
formul
depend
sever
factor
natur
antigen
desir
immun
respons
characterist
level
toler
local
reactogen
aqueou
dispers
mpl
isoton
buffer
admix
solubl
protein
antigen
provid
strong
adjuv
effect
advantag
mpl
plu
antigen
tend
well
toler
induc
littl
local
tissu
reaction
inject
site
qureshi
et
al
mpla
use
enhanc
immun
induc
dna
vaccin
human
immunodefici
viru
type
result
indic
mpl
perform
effect
adjuv
immunogen
dna
inject
despit
reduc
express
encod
protein
muscl
sasaki
et
al
combin
mpl
antigenencod
dna
shown
enhanc
protect
neutral
antibodi
respons
glycoprotein
cv
rabi
viru
lodmel
et
al
lipid
also
admix
plasmid
dna
pdna
coat
nanoparticl
studi
immunolog
potenti
immunolog
result
reveal
plasmid
dna
lipid
shown
signific
higher
immunolog
respons
especi
cellular
respons
cui
mumper
b
studi
indic
la
potenti
adjuv
enhanc
immun
respons
howev
limit
studi
util
adjuv
dna
vaccin
sever
establish
method
util
transfer
plasmid
dna
cell
includ
calcium
phosphat
precipit
electropor
particl
bombard
liposom
deliveri
polymer
deliveri
viralvector
deliveri
receptormedi
gene
deliveri
howev
compar
viral
vector
nonvir
vector
easi
make
less
like
produc
immun
reaction
edelman
tacket
addit
replic
reaction
requir
engin
novel
nanoconstruct
may
deliv
immunogen
safe
appropri
kinet
appropri
locat
possibl
togeth
adequ
recognit
matur
stimuli
fig
use
nonvir
particul
carrier
dnabas
vaccin
could
provid
better
safe
deliveri
encapsul
genet
materi
circumv
need
muscl
involv
facilit
instead
uptak
fig
schemat
represent
immunolog
respons
greet
novel
dnaload
nanocarri
dna
apc
howev
transfect
apc
encapsul
dna
particul
carrier
system
depend
upon
choic
carrier
surfac
charg
size
lipidpolym
composit
presenc
biolog
eg
interleukin
toxic
transfect
effici
nucleic
acid
na
degrad
free
na
releas
challeng
problem
current
nonvir
gene
deliveri
system
includ
lipid
polym
carrier
system
pouton
et
al
cui
mumper
b
one
current
trend
dna
vaccin
formul
use
biodegrad
polymer
microparticl
liposom
deliveri
system
dna
vaccin
excel
formul
deliveri
enhanc
immunogen
sever
differ
host
like
mice
nonhuman
primat
human
herrmann
et
al
kaur
et
al
note
earlier
genet
materi
attach
particul
carrier
like
bring
success
immunolog
reaction
chitosan
particl
act
adjuv
right
natur
polym
gelatin
albumin
use
particul
drug
deliveri
system
although
uncertain
puriti
certainli
potenti
immunogen
pouton
et
al
cui
mumper
b
xiang
et
al
pichichero
plasmid
dna
trap
surfac
polym
like
polylacticecoglycolid
chitosan
polyethyleneimin
aminefunction
polymethacryl
cation
poli
ester
poloxam
polyvinylpyrrolidon
densmor
polymertrap
plasmid
dna
deliv
system
directli
mucos
surfac
oral
via
respiratori
tract
complex
taken
dendrit
cell
dc
result
upregul
dc
activ
marker
augment
system
mucos
immun
respons
liposom
offer
consider
flexibl
toward
vaccin
optim
due
structur
versatil
includ
vesicl
surfac
charg
cation
anion
liposom
made
size
lipid
content
liposom
suitabl
adjuv
protect
dna
degrad
serum
protein
transfer
dna
across
membran
releas
genet
materi
follow
fusion
endosom
gao
huang
nakanishi
noguchi
among
differ
approach
drug
deliveri
lipid
vesicl
hydrophob
hydrophil
drug
attract
much
attent
lipidbas
gene
deliveri
focu
sever
special
hightechnolog
compani
vical
san
diago
ca
usa
genzym
farmington
usa
genemedicin
woodland
tx
usa
megabio
burlingam
ca
usa
product
clinic
trial
engin
liposom
nonliposom
version
like
phsensit
cation
anion
liposom
phsensit
immunoliposom
fusogen
liposom
genosom
dnaliposomeslipid
complex
lipofect
tm
lipiddna
complex
recent
cochleat
investig
major
gene
vector
fig
howev
commerci
avail
nonvir
gene
vector
use
transfect
cation
liposomedna
complex
fensk
culli
liposom
selfassembl
structur
compris
concentr
amphipath
lipid
eg
phospholipid
bilay
separ
aqueou
compart
bacaestrada
et
al
saup
et
al
first
humor
immun
respons
observ
mice
inject
liposomeentrap
diphtheria
toxoid
allison
gregoriadi
manesi
et
al
liposom
vaccin
investig
inhuman
trial
includ
malaria
hiv
hepat
influenza
prostat
cancer
colorect
cancer
katr
et
al
liposomebas
drug
deliveri
system
genet
materi
encapsul
liposom
administ
patient
treat
advantag
use
liposom
dna
may
taken
directli
apc
dendrit
cell
result
transfect
mhc
class
ii
express
stimul
cell
antigen
peptid
induc
ctl
respons
also
b
cell
produc
antibodi
wherea
vaccin
nake
plasmid
dna
plasmid
taken
myocyt
transfect
unfortun
number
problem
associ
use
convent
liposom
genet
vaccin
deliveri
vehicl
rel
low
transfect
liposom
particularli
evid
insuffici
quantiti
polynucleotid
within
liposom
formul
overcom
ad
posit
charg
amphipath
lipid
moieti
liposom
formul
sever
phospholipid
may
use
prepar
liposom
entrap
vaccin
includ
phosphatidylcholin
phosphatid
acid
triolein
phosphatidylglycerol
phosphatidylserin
distearoyl
phosphatidylcholin
dioleylphosphatidylethanolamin
phosphatidylethanolamin
polyethyleneglycol
etc
overal
modif
system
may
provid
high
membran
fluiditi
flexibl
endocytosi
fusiogen
behavior
make
system
far
better
particul
carrier
fig
cation
liposom
wide
explor
nowaday
deliveri
dna
eukaryot
form
simpl
mix
posit
charg
lipid
bilay
neg
charg
nake
dna
result
cation
liposomesdna
complex
lipoplex
taken
via
endocytosi
follow
releas
earli
endosom
compart
duzgun
et
al
cation
lipiddna
complex
use
success
deliv
plasmid
dna
lung
brain
tumor
skin
local
administr
vascular
endotheli
cell
system
intraven
inject
brigham
et
al
addit
differ
cation
lipid
fig
also
shown
import
role
membran
perturb
fusion
intracellular
deliveri
genet
materi
liu
et
al
shown
lipoplex
show
much
higher
transfect
liver
nake
dna
alon
liu
et
al
gregoriadi
et
al
first
time
show
intramuscular
immun
mice
prccmv
hb
encod
region
hepat
b
antigen
hbsag
entrap
posit
charg
cation
liposom
lead
greatli
improv
humor
cellmedi
immun
gregoriadi
et
al
cation
liposomeentrap
dna
vaccin
gener
titer
antihbsag
antibodi
isotyp
excess
higher
increas
level
compar
nake
dna
dna
complex
preform
similar
cation
liposom
modif
liposom
surfac
polym
offer
potenti
oral
administr
plasmid
dna
abl
elicit
markedli
enhanc
transgenespecif
cytokin
product
follow
vitro
restimul
splenocyt
recombin
antigen
somavarapu
et
al
modif
lipiddna
complex
polym
poli
llactic
acid
found
consist
significantli
effect
either
unmodifi
liposom
dna
nake
dna
elicit
transgenespecif
immun
respons
plasmidencod
antigen
administ
sc
rout
bramwel
et
al
surfacemodifi
mannosyl
cation
liposom
develop
target
deliveri
pdna
apc
result
verifi
man
lipoplex
induc
significantli
higher
pubm
gene
transfect
dendrit
cell
macrophag
unmodifi
lipoplex
nake
dna
also
strongli
induc
ctl
activ
melanoma
inhibit
growth
prolong
surviv
tumor
challeng
compar
unmodifi
liposom
lu
et
al
anion
lipid
formul
call
fluid
liposom
capabl
deliv
fluoresc
label
oligonucleotid
bacteri
cell
compos
dppc
phosphorac
dmpg
lack
progress
system
may
attribut
poor
associ
dna
molecul
anion
lipid
electrostat
repuls
neg
charg
speci
perri
gregoriadi
liposom
prepar
mixtur
anion
zwitter
ionic
lipid
dope
respect
molar
ratio
dopg
dope
effici
rel
safe
dna
transfect
use
anion
lipoplex
make
altern
gene
deliveri
patil
et
al
similarli
endosomolyt
bacteri
protein
listeriolysin
llo
incorpor
anion
liposomeentrap
polycationcondens
dna
deliveri
system
lpdii
develop
demonstr
better
condens
dna
improv
transfect
effici
due
endosomolyt
properti
llo
lorenzi
lee
combin
cation
lipoplex
pegyl
anion
liposom
also
use
prepar
anion
pegyl
lipoplex
studi
demonstr
gene
express
develop
formul
similar
cation
formul
taken
control
anion
formul
prepar
mignet
et
al
overal
anion
lipoplex
formul
shown
promis
nonvir
vector
hightransfect
effici
low
cytotox
grow
amount
literatur
describ
role
phsensit
liposom
target
andor
releas
encapsul
genet
materi
within
cellular
compart
phsensit
liposom
design
releas
content
respons
acid
ph
within
endosom
system
remain
stabl
plasma
thu
improv
cytoplasm
deliveri
biopharmaceut
gener
insert
dope
acid
lipid
liposom
cholesteryl
hemisuccin
oleic
acid
venugopalan
et
al
report
deterg
remov
method
superior
method
prepar
glycosaminoglycanresist
phsensit
lipidco
dna
complex
method
produc
stabl
acid
activat
lipidco
dna
complex
lehtinen
et
al
neutral
cellular
ph
lipid
undergo
proton
collaps
nonbilay
structur
endosom
compartment
turn
help
rapid
releas
dna
cytoplasm
recent
citraconyldop
chemic
deriv
dope
deliv
dnabas
therapeut
cancer
cell
manner
combin
target
rapid
endosom
releas
reddi
low
addit
phsensit
fusogen
peptid
gala
peptid
compos
repeat
sequenc
glualaleuala
lipid
prepar
also
promis
method
enhanc
express
desir
protein
studi
demonstr
addit
gala
plasmidliposom
complex
significantli
increas
transfect
effici
especi
case
lipofectin
higher
concentr
gala
decreas
transfect
effici
futaki
et
al
nakas
et
al
similarli
phsensit
histidinemodifi
galactosyl
cholesterol
deriv
also
synthes
demonstr
much
greater
transfect
activ
convent
liposom
hepat
cell
shigeta
et
al
phsensit
tatmodifi
pegyl
liposom
util
deliveri
tumorspecif
stimulisensit
drug
gene
deliveri
system
kale
torchilin
immunoliposom
sophist
gene
deliveri
system
incorpor
function
antibodi
attach
lipid
bilay
use
cell
target
maclean
et
al
use
immunoliposom
tissuespecif
gene
deliveri
achiev
brain
embryon
breast
cancer
tissu
recent
immunoliposom
contain
antibodi
fragment
success
use
target
deliveri
tumorsuppress
gene
tumor
vivo
xu
et
al
chloramphenicol
acetyltransferas
cat
geneencod
plasmid
entrap
phsensit
immunoliposom
compris
antibodyco
liposom
dope
cholesterol
oleic
acid
studi
reveal
approxim
inject
immunoliposom
taken
target
cell
uptak
much
less
liposom
without
antibodi
use
wang
huang
similarli
author
also
report
composit
liposom
alter
distribut
target
drug
deliveri
also
depend
lipid
composit
liposom
phsensit
lipid
composit
gave
eightfold
higher
effici
correspond
phinsensit
composit
wang
huang
ligandmodifi
immunoliposom
use
effici
deliv
plasmid
dna
express
hcvspecif
antigen
sequenc
antigenpres
cell
result
confirm
effici
deliveri
system
direct
intramuscular
inocul
nake
dna
zubkova
et
al
overal
studi
shown
immunoliposom
effici
use
target
deliveri
genet
materi
especi
treatment
genet
disord
howev
limit
work
done
deliveri
dna
vaccin
stealth
liposom
polyethylen
glycol
peg
conjug
lipid
steric
stabil
liposom
formul
pegyl
prevent
liposom
vesicl
opson
recognit
reticuloendotheli
system
conjunct
polymer
deliveri
system
pll
achiev
longer
circul
halfliv
mannisto
et
al
peg
graft
liposom
carri
antigen
epitop
transmembran
protein
shown
higher
immun
respons
prolong
persist
antibodi
plain
liposomebas
antigen
formul
singh
bisen
also
report
graft
peg
cation
liposom
result
enhanc
lymphat
drainag
improv
immun
respons
compar
nonpegyl
liposom
carsten
et
al
similarli
immun
cellspecif
ligand
anchor
pegyl
liposom
develop
provid
select
uptak
immunolog
cell
ultrasound
us
respons
mannosemodifi
gene
carrier
manpeg
bubbl
lipoplex
util
transfer
ovalbumin
ova
express
plasmid
dna
select
effici
antigenpres
cell
develop
system
demonstr
higher
gene
express
antigenpres
cell
apc
select
vivo
compar
convent
lipofect
method
un
et
al
virosom
lipid
envelop
devoid
genet
inform
retain
antigen
profil
fusogen
properti
viral
origin
reconstitut
lipid
vesicl
equip
viral
glycoprotein
seem
possess
mani
ideal
properti
deliveri
immunogen
limit
size
encapsul
immunogen
high
effici
cytosol
deliveri
simplic
handl
breviti
incub
time
okamoto
et
al
virosomemedi
deliveri
low
toxic
high
immunogen
variou
prospect
applic
treatment
prevent
cancer
neurodegen
disord
infecti
diseas
use
immunopotenti
reconstitut
influenza
virosom
iriv
deliveri
system
dna
appear
promis
tool
vaccinolog
gene
therapi
iriv
spheric
unilamellar
vesicl
mean
diamet
nm
short
surfac
project
nm
iriv
prepar
mixtur
natur
synthet
phospholipid
contain
egg
yolk
phosphatidylcholin
enhanc
immun
respons
synthet
phosphatidylethanolamin
abl
directli
stimul
b
cell
produc
antibodi
envelop
phospholipid
origin
influenza
viru
iriv
first
util
manufactur
hepat
vaccin
adjuv
function
virosom
base
viruslik
particl
structur
provid
repetit
antigen
present
b
cell
partial
protect
extracellular
degrad
depot
effect
gluck
et
al
proteasom
immunogen
deliveri
system
gener
use
noncoval
interact
proteosom
antigen
form
appropri
complex
deliv
apolar
amphiphil
antigen
case
trial
involv
intranas
administr
vaccin
qualifi
safe
welltoler
materi
variou
human
clinic
trial
proteasomeconjug
shigella
flexneri
lp
vaccin
show
immun
respons
similar
observ
immun
live
pathogen
fri
et
al
intranas
deliveri
proteasomebas
vaccin
may
abl
produc
system
mucos
immun
anoth
similar
categori
vaccin
conjug
vaccin
vaccin
consist
rel
nonimmunogen
especi
infant
antigen
link
immunogen
carrier
protein
toxoid
conjug
vaccin
h
influenza
type
b
hib
develop
use
hib
polysaccharid
conjug
either
diphtheria
toxoid
prpd
omp
neisseria
meningitidi
prpomp
mutant
diphtheria
toxoid
hboc
tetanu
toxoid
prpt
provid
hib
antigen
immunogen
heath
cochleat
phospholipid
calcium
precipit
uniqu
structur
consist
larg
continu
solid
lipid
bilay
sheet
roll
jelli
rolllik
structur
papahadjopoulo
et
al
cochleat
deliveri
vehicl
compos
simpl
natur
materi
phosphatidylserin
calcium
uniqu
vaccin
carrier
deliveri
formul
mannino
gouldfogerit
nontox
noninflammatori
biodegrad
cochleat
prepar
calciuminduc
fusion
neg
charg
phospholipid
liposom
collaps
solid
sheet
roll
stack
exclud
water
entir
cochleat
structur
seri
solid
layer
compon
within
interior
cochleat
structur
remain
intact
provid
protect
degrad
expos
harm
environment
condit
enzym
protect
encochl
materi
structur
stabil
cochleat
allow
effici
deliveri
dna
variou
rout
like
mucos
oral
intragastr
intranas
intraocular
parenter
intramuscular
subcutan
intraperiton
intraderm
strong
longlast
mucos
circul
antibodi
cellmedi
respons
gener
protect
challeng
live
virus
follow
oral
intramuscular
administr
achiev
mannino
et
al
cochleat
effici
improv
attach
surfac
glycoprotein
envelop
virus
integr
lipid
bilay
dna
cochleat
form
trap
oligonucleotid
high
molecular
weight
plasmid
within
lipid
bilay
papahadjopoulo
et
al
viruslik
particl
vlp
small
particl
consist
one
viral
coat
protein
act
adjuv
carri
peptid
sequenc
insid
apc
feed
endogen
process
pathway
schirmbeck
et
al
safe
highli
immunogen
addit
adjuv
need
well
toler
noninfect
easili
handl
laboratori
use
natur
mechan
structur
principl
trigger
immun
system
protect
effect
stimul
cellular
immun
effect
stimul
prolif
respons
cytotox
lymphocyt
ctl
respons
humor
immun
effici
crosslink
membraneassoci
immunoglobulin
molecul
constitut
bcell
receptor
chackerian
jen
bachmann
buonaguro
et
al
immunestimul
complex
iscom
highli
versatil
effect
particul
antigen
deliveri
system
extens
studi
adjuv
system
rang
viral
bacteri
parasit
antigen
iscom
threedimension
cagelik
structur
shown
form
upon
deterg
remov
mixtur
saponin
deterg
cholesterol
iscom
immunostimul
complex
complex
consist
protein
antigen
cholesterol
phospholipid
saponin
adjuv
quil
similar
vaccin
deliveri
vehicl
adjuv
also
develop
use
materi
minu
antigen
refer
iscomatrix
antigen
ad
later
iscomatrix
formul
vaccin
materi
seem
work
similarli
iscom
provid
gener
applic
remov
requir
hydrophob
antigen
pears
drane
iscom
potenti
humor
cellular
immun
respons
incorpor
antigen
cox
et
al
iscom
stimul
apc
produc
induc
thelper
cell
type
cellmedi
immun
respons
includ
class
restrict
cytotox
cell
varieti
experiment
anim
model
progress
phase
ii
human
trial
claassen
osterhau
barr
mitchel
oral
administr
iscom
vaccin
shown
effect
immunepotenti
effect
rout
requir
use
high
frequent
dose
studi
iscom
vaccin
may
abl
elicit
strong
mucos
immun
respons
administ
pelvic
presacr
space
sheep
could
use
immun
viral
infect
femal
genit
tract
thapar
et
al
quil
acontain
iscom
modifi
cholera
toxin
use
mucos
vaccin
carrier
system
influenza
viru
antigen
helgebi
et
al
ji
et
al
nasal
vaccin
dna
vaccin
matrixm
immunostimulatori
complex
adjuv
shown
signific
higher
igaproduc
cell
addit
cytokin
express
strategi
may
provid
new
way
induct
specif
immun
mucos
site
kodama
et
al
archaeosom
nanometr
size
liposom
made
polar
ether
lipid
archaea
found
eukaryot
bacteria
polar
ether
lipid
archaeosom
provid
excel
physicochem
stabil
selfadjuv
properti
deliveri
vaccin
prepar
archaeosom
demonstr
rel
higher
stabil
oxid
stress
high
temperatur
alkalin
ph
action
phospholipas
bile
salt
serum
protein
patel
chen
benvegnu
et
al
archaeosom
facilit
strong
antibodi
respons
entrap
protein
antigen
antibodi
humor
respons
superior
obtain
convent
liposom
instanc
compar
obtain
potent
toxic
freund
adjuv
patel
sprott
patel
chen
sprott
et
al
also
describ
role
coenzym
archaeosomebas
antigen
formul
incorpor
archaeosom
convent
liposom
enhanc
phagocytosi
result
vesicl
macrophag
cell
allow
alter
target
profil
specif
tissu
vesicl
administ
anim
via
differ
rout
enhanc
immun
respons
coadminist
immunogen
recent
cation
archaeosom
base
mixtur
neutralcation
bilayerform
lipid
archaeobacteri
synthet
tetraethertyp
bipolar
lipid
shown
better
transfect
effici
util
dna
vaccin
rethor
et
al
among
varieti
lipid
deliveri
system
polymer
deliveri
system
emerg
promis
altern
eas
prepar
purif
chemic
modif
well
enorm
stabil
polymer
nonvir
carrier
polyplex
one
effect
mean
deliv
therapeut
biolog
activ
substanc
control
sustain
manner
polymer
particul
deliveri
system
induc
adjuv
effect
incorpor
antigen
reduc
frequenc
vaccin
requir
establish
longterm
protect
natur
synthet
polym
consid
encapsul
antigen
materi
vaccin
tabl
variou
polymer
deliveri
system
develop
use
polym
like
micellar
system
emuls
polymerosom
nanoparticl
microspher
nanocapsul
dendrim
dendrosom
fig
howev
sever
associ
concern
use
polym
vaccin
deliveri
system
toxic
irrit
allergen
biodegrad
advantag
use
natur
polym
includ
low
cost
biocompat
aqueou
solubl
howev
natur
polym
may
also
limit
use
due
presenc
extran
contamin
variabl
lot
lot
low
hydrophob
contrast
synthet
polym
reproduc
prepar
desir
degrad
rate
molecular
weight
copolym
composit
nevertheless
synthet
polym
may
disadvantag
due
limit
solubl
often
solubl
organ
solvent
consequ
may
releas
biolog
activ
antigen
riceficht
et
al
polymer
vaccin
may
offer
improv
stabil
activ
encapsul
antigen
materi
avoid
exposur
organ
solvent
use
formul
acid
ph
condit
caus
degrad
polym
duncan
et
al
effect
applic
polymer
nanoparticul
deliveri
system
greatli
depend
specif
polym
use
dictat
properti
nanoparticl
vivo
hanson
et
al
exampl
polycation
polym
interact
neg
charg
dna
result
improv
intracellular
dna
deliveri
occur
wherea
noncondens
polym
neutral
slightli
neg
charg
polym
physic
encapsul
materi
use
target
apc
mcell
mucosa
bhavsar
amiji
number
factor
affect
physicochem
properti
polymer
deliveri
vehicl
like
molecular
weight
degre
branch
cation
charg
densiti
buffer
capac
polyplex
properti
experiment
condit
like
polyplex
concentr
presenc
absenc
serum
transfect
incub
time
transfect
model
chosen
gene
deliveri
experi
reduc
cytotox
improv
transfect
effici
polyplex
modifi
conjug
polyethylen
glycol
peg
histidin
target
ligand
includ
polysaccharid
transferrin
galactos
variou
biodegrad
polym
like
aliphat
polyest
poli
lactic
acid
pla
poli
glycol
acid
pga
poli
ecaprolacton
pcl
poli
hydroxybutyr
phb
copolym
evalu
use
vaccin
adjuv
deliveri
system
panyam
labhasetwar
recent
poli
amino
acid
sbase
copolym
also
employ
deliveri
protein
vaccin
genet
materi
polylglutam
acid
polylaspart
acid
polyllysin
polylarginin
polylprolin
polylasparagin
polylhistidin
polyamino
acid
properti
mimic
protein
make
ideal
vaccin
deliveri
provid
better
adjuvant
low
toxic
biodegrad
target
intracellular
compart
chiang
yeh
variou
type
polysaccharid
agaros
algin
carrageenan
hyaluron
acid
dextran
chitosan
cyclodextrin
mannan
pullulan
use
deliveri
vaccin
tabl
specif
concentr
temperatur
amphiphil
molecul
molecul
contain
hydrophob
hydrophil
region
maintain
natur
form
associ
colloid
known
amphiphil
micel
result
hydrophob
interact
poli
ethylen
glycol
peg
commonli
incorpor
hydrophil
segment
amphiphil
micel
gaucher
et
al
gelatin
denatur
protein
obtain
acid
alkalin
process
collagen
insolubl
water
prepar
hydrogel
chemic
crosslink
watersolubl
carbodiimid
glutaraldehyd
lou
et
al
easi
process
good
biodegrad
poor
mechan
properti
brittl
capabl
target
fibronectinbear
surfac
associ
tumor
silk
fibroin
silkworm
bombyx
mori
produc
silk
weav
cocoon
major
compon
fibroin
sericin
light
weight
extrem
strong
elast
exhibit
mechan
properti
compar
best
synthet
fiber
produc
modern
technolog
zhang
et
al
environment
safe
biocompat
excel
mechan
properti
less
product
high
brittl
model
antigen
enhanc
stabil
c
month
fibrin
fibrin
protein
matrix
produc
fibrinogen
provid
immunecompat
carrier
deliveri
activ
biomolecul
antigen
fibrin
natur
contain
site
cell
bind
investig
substrat
cell
linkag
distribut
reloc
propag
khan
et
al
induc
improv
cellular
interact
use
cell
carrier
well
antigen
carrier
rapid
degrad
instabl
low
mechan
stiff
elastin
elastin
synthes
vascular
smooth
muscl
cell
secret
tropoelastin
monom
solubl
hydrophob
nonglycosyl
elastin
potent
regul
vascular
smooth
muscl
cell
activ
regul
import
prevent
fibrocellular
patholog
gaudreau
et
al
confer
elast
precis
molecular
weight
low
polydispers
becom
insolubl
aggreg
critic
temperatur
soybean
cultiv
plant
world
rich
protein
carbohydr
lipid
speci
legum
nativ
process
proteinrich
product
moravec
et
al
abund
renew
inexpens
environ
friendli
biodegrad
applic
soybas
polym
field
still
narrow
iga
mucos
iga
antibodi
respons
administ
oral
mice
chitosan
fullyparti
deacetyl
form
chitin
degre
deacetyl
commerci
chitosan
usual
molecular
weight
kda
chitosan
exhibit
phsensit
behavior
weak
polybas
due
larg
quantiti
amino
group
chain
verheul
et
al
enhanc
immun
respons
mucoadhes
properti
poli
esteramid
polym
made
soft
peg
segment
connect
hard
diesterdiamid
segment
ether
bond
high
perform
thermoplast
elastom
use
replac
common
elastomersthermoplast
polyurethan
polyest
elastom
siliconesfor
characterist
lower
densiti
among
tpe
superior
mechan
dynam
properti
flexibl
impact
resist
energi
return
fatigu
resist
keep
properti
low
temperatur
lower
c
good
resist
wide
rang
chemic
sensit
uv
degrad
li
hu
enhanc
cell
mediat
immun
superior
mechan
thermal
properti
poli
lactidecoglycolid
plga
plga
poli
lacticcoglycol
acid
copolym
synthes
mean
random
ringopen
copolymer
two
differ
monom
cyclic
dimer
glycol
acid
lactic
acid
polymer
success
monomer
unit
glycol
lactic
acid
link
togeth
plga
ester
linkag
thu
yield
linear
aliphat
polyest
product
moor
et
al
degrad
product
natur
occur
metabolit
readili
absorb
neighbor
cell
gener
acid
environ
effect
stabil
yersinia
pesti
hiv
domin
respons
block
copolym
micel
colloid
particl
size
around
nm
current
investig
carrier
deliveri
biopharmaceut
contrast
cation
polymer
system
nonion
polym
enhanc
gene
express
mechan
like
involv
dna
condens
facilit
transport
within
cell
adjuvantact
nonion
block
copolym
flexibl
linear
structur
flank
end
hydrophil
polyoxyethylen
poe
core
hydrophob
polyoxypropylen
pop
variabl
ratio
newman
et
al
block
copolym
use
gener
surfact
display
enhanc
biolog
efficaci
vaccin
adjuv
osmolar
ph
buffer
salt
mainli
affect
size
morpholog
particl
molecular
weight
formul
mainli
affect
titer
isotyp
antibodi
jain
et
al
evalu
system
combin
poli
lactic
acid
pla
poli
ethylen
glycol
peg
deliveri
recombin
hepat
b
surfac
antigen
hbsag
pla
form
hydrophob
core
aqueou
medium
control
releas
antigen
degrad
lactic
acid
outer
shell
form
peg
allow
prolong
releas
pattern
enhanc
mucos
uptak
occur
jain
et
al
hunter
et
al
show
adjuv
activ
block
copolym
vari
length
chain
polyoxypropylen
pop
polyoxyethylen
poe
pluron
block
copolym
use
extens
varieti
pharmaceut
formul
like
low
molecular
mass
drug
polypeptid
kabanov
et
al
describ
molecul
modifi
biolog
respons
gene
therapi
skelet
muscl
result
enhanc
transgen
express
therapeut
effect
transgen
block
copolym
recent
use
promot
gene
deliveri
plasmid
encod
food
allergen
bovin
betalactoglobulin
tetron
base
block
copolym
decreas
blgspecif
ige
concentr
reduc
local
inflammatori
respons
adelpati
et
al
similarli
triblock
copolym
consist
three
altern
hydrophob
hydrophil
segment
also
use
deliveri
genet
materi
biodegrad
nontox
triblock
copolym
plapegpla
plgapegplga
also
util
micellar
carrier
deliveri
encapsul
plasmid
hcv
develop
carrier
system
provid
longterm
better
adjuv
effect
side
effect
yang
et
al
similarli
copolym
hydrophil
poli
ethylen
glycol
block
cation
poli
aminoethyl
methacryl
paem
block
use
dna
vaccin
deliveri
synthes
polyplex
base
carrier
system
induc
modest
upregul
surfac
marker
dc
matur
better
uptak
dc
drain
lymph
node
tang
et
al
cation
block
copolym
poli
ethylen
glycol
peg
posit
charg
poli
dimethylamino
ethyl
methacryl
synthes
util
tat
dna
molecul
result
indic
synthes
cation
block
copolym
safe
abil
deliv
genet
materi
cell
machineri
promis
candid
dna
vaccin
caputo
et
al
similar
cation
block
polym
nonion
block
copolym
poli
ethyleneoxid
poli
propyleneoxid
peoppo
also
util
dna
vaccin
use
betagalactosidas
betag
encod
plasmid
mcilroy
et
al
herp
simplex
viru
gene
specifi
glycoprotein
gb
gd
also
deliv
nonion
block
copolym
plasmidencapsul
block
polym
protect
mice
lethal
challeng
immun
perform
via
im
rout
baghian
et
al
dendrim
uniqu
class
polymer
nanoconstruct
highli
branch
threedimension
nanoscal
architectur
low
polydispers
high
function
first
discov
earli
donald
tomalia
cowork
hyperbranch
molecul
call
dendrim
dendrim
highli
branch
synthet
spheric
macromolecul
layer
architectur
consid
analog
globular
protein
potenti
high
load
capac
due
small
diamet
nm
mechan
complex
format
chemic
bond
termin
branch
point
activ
site
wiwattanapatape
et
al
addit
low
polydispers
dendrim
provid
reproduc
pharmacokinet
behavior
contrast
polym
contain
fraction
vastli
differ
molecular
weight
within
given
sampl
parekh
sever
dendrimerbas
product
approv
fda
success
commerci
treatment
diagnosi
diseas
includ
starpharma
design
topic
microbicid
superfect
qiagen
pvt
ltd
use
gene
transfect
alert
us
armi
research
lab
anthrax
detect
merdan
et
al
past
decad
research
increas
polyamidoamin
polyethylenimin
polylysin
polypropyleneimin
polyaryl
ether
polyest
polyglycerol
deriv
design
synthesi
biocompat
dendrim
dendrim
form
complex
electrostat
interact
form
nucleic
acid
dna
rna
antisens
oligonucleotid
natur
dendrimernucl
acid
complex
dendriplex
depend
stoichiometri
concentr
dnaphosph
dendrim
amin
bulk
solvent
properti
eg
ph
salt
concentr
buffer
strength
even
dynam
mix
high
ionic
strength
interfer
bind
process
affect
natur
complex
form
differ
gener
exampl
highergener
ppi
dendrim
higher
concentr
form
watersolubl
dendriplex
wherea
ppi
dendrim
lead
format
electroneutr
complex
tang
szoka
dendrimerdna
complex
form
simpli
mix
compon
aqueou
solut
transfect
properti
improv
use
excess
cation
dendrim
neg
charg
phosphat
group
dna
neutral
posit
charg
amin
group
dendrim
electrostat
interact
overal
posit
charg
system
import
cell
uptak
bielinska
et
al
immunogen
efficaci
dna
vaccin
improv
physic
conjug
pamam
dendrim
mhc
class
iitarget
peptid
therefor
dendrim
explor
dnabas
vaccin
develop
malaria
parasit
pietersz
et
al
recent
studi
dendriplex
complex
dendron
condens
plasmid
contain
gene
protect
antigen
pa
bacillu
anthraci
encapsul
polylactidecoglycolid
plg
particl
use
doubl
emuls
method
studi
indic
plgdendriplex
particl
produc
superior
level
antipa
igg
antibodi
compar
anim
immun
plg
particl
ribeiro
et
al
conjug
fifthgener
polyamidoamin
dendrim
dnaload
surfac
mhc
class
iitarget
peptid
select
deliv
dendrim
apc
condit
enhanc
immun
stimulatori
potenc
dna
conjug
platform
effici
transfect
murin
human
apc
vitro
subcutan
administr
dnapeptidedendrim
complex
vivo
preferenti
transfect
dendrit
cell
dc
drain
lymph
node
promot
gener
high
affin
cell
elicit
reject
establish
tumor
taken
togeth
find
show
pamamdendrim
complex
use
high
transfect
effici
effect
target
apc
vivo
confer
properti
essenti
gener
effect
dna
vaccin
multipl
antigen
peptid
map
dendrim
system
use
vaccin
immun
purpos
mapbas
deliveri
prepar
addit
multipl
immunefunct
compon
like
btcell
epitop
cellpenetr
peptid
lipophil
moieti
control
synthesi
nanomateri
like
micel
dendrim
nanoparticl
fujita
taguchi
tetraval
multipl
antigen
peptid
map
dendrim
four
ident
branch
ctermin
peptid
sequenc
rat
ghbp
synthes
use
immunogen
rabbit
tetraval
rat
map
dendrim
serv
effect
immunogen
antigen
elicit
specif
antibodi
aguilar
et
al
similar
map
dendrim
glycopeptid
dendrim
contain
carbohydr
peptid
also
use
deliveri
vaccin
compon
niederhafn
et
al
sebestik
et
al
encapsul
dendrimernucl
acid
complex
within
lipophil
shell
known
dendrosom
novel
vesicular
spheric
supramolecular
entiti
possess
neglig
hemolyt
toxic
higher
transfect
effici
dendrosom
report
complet
nontox
vitro
well
vivo
poli
propyleneimin
dendrosomebas
genet
immun
found
highli
effect
hepat
b
compar
dendrimerplasmid
dna
complex
result
indic
dendrosom
hold
great
potenti
dna
vaccin
dendrosom
poli
propyleneimin
dendrimerdna
complex
larg
protect
multilamelar
vesicl
report
polyamidoamin
dendrimerbas
dendrosom
effici
system
deliveri
target
oncogen
cervic
cancer
pourasgari
et
al
vitro
superior
transfect
effici
display
pamam
dendrosom
comparison
nonvir
gene
deliveri
vector
nontox
selfassembl
dendrit
spheroid
nanoparticl
use
deliveri
load
dendrit
spheroid
nanoparticl
shown
low
toxic
enhanc
transfect
effici
improv
immun
respons
birch
pollen
allergi
balenga
et
al
similarli
effici
dendrosom
gene
porter
assess
transfer
recombin
human
rotaviru
cdna
studi
reveal
dendrosom
lower
cytotox
better
transfect
human
lung
cell
line
pourasgari
et
al
dendrosom
use
deliv
dna
vaccin
encod
gene
studi
prove
efficaci
carrier
deliveri
recombin
plasmid
construct
roodbari
et
al
polymersom
selfassembl
polymer
colloid
vesicular
system
contain
aqueou
inner
core
polymersom
made
amphiphil
block
copolym
allow
polymersom
stabli
encapsul
integr
broad
rang
activ
molecul
aqueou
core
util
encapsul
therapeut
hydrophil
molecul
membran
integr
hydrophob
drug
within
hydrophob
part
brushlik
surfac
properti
polymersom
provid
better
biocompat
blood
circul
time
system
better
load
effici
stabil
provid
sustain
control
releas
encapsul
therapeut
system
also
use
deliv
biotherapeut
especi
peptid
protein
nucleic
acid
sitespecif
cellular
environ
due
escap
endolysosom
levin
et
al
christian
et
al
amphiphil
diblock
copolym
poli
oligoethylen
glycol
methacryl
blockpoli
diisopropylamino
ethyl
methacryl
associ
tannic
acid
form
dnaload
polymersom
develop
system
demonstr
better
cytosol
releas
encapsul
nucleic
acid
materi
loma
et
al
calceinload
polymersom
also
observ
cytosol
deliveri
within
dendrit
cell
scott
et
al
similarli
poli
gbenzyllglutam
k
polymersom
use
deliveri
influenza
hemagglutinin
antigen
immunogen
adjuvant
develop
polymerosom
better
administ
influenza
antigen
futur
nanostructur
polymer
vesicular
system
may
huge
potenti
deliveri
protein
dna
vaccin
emuls
manufactur
waterinoil
wo
oilinwat
ow
particul
carrier
system
emuls
carrier
system
similar
size
pathogen
taken
epitheli
cell
mucos
surfac
success
deliveri
vaccin
compon
apc
lymphoid
tissu
nanoemuls
formul
intranas
hepat
b
vaccin
show
improv
vaccin
efficaci
stabil
eas
distribut
makidon
et
al
multipl
emuls
formul
also
use
vaccin
carrier
system
due
longer
stabil
high
entrap
effici
protein
antigen
without
damag
emulsif
procedur
type
surfact
process
method
stabil
requisit
make
stabl
multipleemuls
hanson
et
al
emuls
adjuv
immunostimul
shown
result
recruit
antigenpres
cell
apc
site
inject
increas
uptak
solubl
antigen
apc
formul
simpl
mix
antigen
adjuv
shown
excel
compat
varieti
subunit
antigen
show
strong
immunogen
comparison
adjuv
clearli
seen
preclin
data
publish
ott
et
al
report
immun
guinea
pig
goat
glycoprotein
herp
simplex
viru
hsv
type
presenc
show
ninefold
increas
antibodi
titer
compar
aluminum
hydroxid
respect
ott
et
al
oilinwat
ow
emuls
syntex
adjuv
formul
saf
effect
adjuv
compos
muramyl
dipeptid
deriv
threonylmdp
threonylmdp
demonstr
lack
side
effect
pyrogen
uveiti
adjuvantinduc
arthriti
increas
adjuv
activ
saf
adjuv
use
varieti
antigen
influenza
malaria
show
cellmedi
humor
immun
respons
saf
suitabl
equival
provid
excel
tool
vaccin
research
lidgat
et
al
lidgat
et
al
sever
differ
type
includ
isa
v
isa
use
human
vaccin
formul
isa
v
use
veterinari
vaccin
formul
compos
metaboliz
squalenebas
oil
mannid
monool
emulsifi
permit
antigen
releas
rapidli
montanid
emuls
induc
high
antibodi
titer
ctl
respons
due
format
depot
site
inject
emuls
use
vaccin
malaria
hiv
variou
cancer
found
safe
fairli
well
toler
lawrenc
et
al
toledo
et
al
variou
physic
deliveri
method
heavili
investig
direct
transfect
apc
dna
vaccin
porgador
et
al
transcutan
microneedl
abil
bypass
stratum
corneum
layer
skin
thu
reach
langerhan
cellsth
apc
skin
jetinject
mechan
devic
deliv
dna
vaccin
viabl
epidermi
increas
efficaci
prevent
andor
therapi
infecti
diseas
allerg
disord
cancer
chen
et
al
imoto
konishi
robert
et
al
tattooperfor
needl
devic
use
punctur
skin
transfer
dna
skinassoci
cell
bundl
fine
metal
needl
oscil
constant
high
frequenc
shown
better
express
report
gene
mice
induct
immun
respons
electropor
extens
studi
deliv
therapeut
gene
encod
varieti
hormon
cytokin
enzym
antigen
larg
anim
speci
dog
pig
cattl
nonhuman
primat
sever
differ
strategi
technolog
pursu
howev
littl
current
known
sever
devic
much
addit
research
area
warrant
van
drunen
littelvan
den
hurk
et
al
roo
et
al
hirao
et
al
nanotechnolog
develop
engin
devic
due
small
size
micromolecular
level
nanomet
rang
larg
surfac
area
enhanc
action
earli
diagnosi
cancer
infecti
diseas
advanc
nanotechnolog
also
prove
benefici
therapeut
field
drug
discoveri
drug
deliveri
geneprotein
deliveri
concept
found
use
develop
nanovaccin
use
differ
rout
administr
like
oral
nasal
parenter
oral
rout
popular
conveni
rout
administr
oral
deliveri
refer
absorpt
buccal
rectal
mucosa
sever
barrier
associ
genet
vaccin
oral
gener
attribut
low
permeabl
across
biolog
membran
b
harsh
gastric
environ
c
hepat
firstpass
metabol
chemic
instabl
major
drawback
oral
rout
administr
higher
concentr
requir
vaccin
effect
due
dilut
transport
vaccin
gastrointestin
tract
date
gene
deliveri
strategi
concentr
parenter
rout
deliveri
oral
administr
larg
ignor
differ
nanoand
microparticul
deliveri
system
use
natur
synthet
lipid
polym
util
improv
stabil
immunogen
oral
dna
vaccin
bhavsar
amiji
oral
vaccin
dnachitosan
nanoparticl
appear
interest
great
stabil
eas
target
access
besid
chitosan
immunostimulatori
properti
studi
demonstr
protect
parasit
infect
deliveri
chitosan
nanoparticl
load
dna
encod
protein
schistosoma
mansoni
oliveira
et
al
similarli
chitosan
nanoparticl
use
dna
vaccin
vibrio
anguillarum
oral
rout
studi
reveal
chitosandna
complex
show
moder
protect
experiment
v
anguillarum
infect
oral
vaccin
asian
sea
bass
rajesh
kumar
et
al
oral
administ
tresylmonomethoxypolyethylen
glycol
tmpeg
graft
liposom
complex
modifi
vaccinia
viru
ankara
mva
iiibbetag
also
capabl
deliv
transgen
mucos
tissu
enhanc
envspecif
cellular
humor
immun
respons
repeat
oral
immun
balbc
mice
naito
et
al
mannosyl
niosom
load
hepat
dna
shown
humor
system
mucos
cellular
immun
respons
upon
oral
administr
jain
et
al
chitosanco
polyplexload
liposom
pll
contain
plasmid
prccmvhb
develop
oral
deliveri
vaccin
specif
target
peyer
patch
chitosanco
pll
demonstr
better
uptak
encapsul
dna
distal
intestin
provid
better
stabil
enzymat
degrad
channarong
et
al
nasal
rout
chiefli
employ
produc
local
action
mucosa
rout
number
advantag
high
permeabl
nasal
epithelium
allow
higher
molecular
mass
cutoff
permeat
approxim
da
well
rapid
drug
absorpt
rate
accur
repeat
dispens
vaccin
mucociliari
clearanc
presenc
peptidas
proteas
nucleas
enzym
mucu
associ
nasal
membran
variat
extent
absorpt
mucu
secret
mucu
turnov
deposit
formul
vaccin
area
nasal
mucosa
especi
lymphoid
tissu
potenti
uptak
vaccin
formul
primari
olfactori
nerv
nasal
caviti
local
irrit
unpleas
tast
concentr
drug
reach
mouth
major
challeng
associ
intranas
deliveri
vaccin
oliveira
et
al
sharma
et
al
problem
overcom
design
appropri
antigen
carrier
nanocarri
nasal
vaccin
abl
facilit
transport
associ
antigen
across
nasal
epithelium
thu
lead
effici
antigen
present
immun
system
provid
protect
stabil
encapsul
genet
materi
kopinghoggard
et
al
use
mucoadhes
agent
offer
strategi
facilit
increas
resid
time
increas
vaccin
efficaci
alpar
et
al
polycarbophil
pc
polyethylen
oxid
peo
base
insitu
mucoadhes
polym
demonstr
better
nasal
absorpt
plasmid
dna
park
et
al
sever
studi
proven
wide
applic
chitosan
nanoparticl
nasal
deliveri
dna
vaccin
like
sever
acut
respiratori
syndrom
coronaviru
sarscov
raghuwanshi
et
al
pneumococc
surfac
antigen
psaa
xu
et
al
hepat
b
antigenencod
plasmid
khatri
et
al
dna
plasmidexpress
epitop
respiratori
syncyti
viru
iqbal
et
al
sever
modif
chitosan
polym
also
made
improv
potenti
chitosan
nanoparticl
nasal
administr
dna
vaccin
like
prepar
low
molecular
weight
chitosan
develop
water
solubl
chitosan
ntrimethyl
chitosan
etc
blend
poli
lacticcoglycol
acid
plga
polyethylen
oxid
peo
exhibit
capac
associ
releas
plasmid
dna
control
manner
result
show
dnaload
nanoparticl
elicit
significantli
pronounc
immun
respons
compar
nake
plasmid
dna
week
csaba
et
al
drypowd
influenza
virosomesbas
vaccin
also
advantag
mucos
immun
de
jong
et
al
needlefre
nasal
immun
use
nanoemuls
made
soya
bean
oil
alcohol
water
deterg
emulsifi
droplet
nm
report
safe
effect
hepat
b
vaccin
makidon
et
al
releas
liquid
particl
airflow
enter
one
nostril
via
seal
nozzl
exit
nostril
minim
risk
problem
relat
deposit
particl
lung
occur
convent
inhal
nebul
increas
deliveri
particl
posterior
part
nasal
mucosa
encapsul
antigen
bioactiv
nanoparticl
promis
approach
nasal
vaccin
deliveri
slutter
et
al
ocular
rout
hold
immens
potenti
peptidesprotein
intend
patholog
ophthalmolog
condit
eye
mucosa
possibl
rout
mucos
vaccin
import
entri
point
environment
antigen
infecti
materi
occupi
extern
ocular
surfac
streilein
et
al
lymphoid
follicl
found
close
associ
epithelium
conjunctiv
mucosa
human
rabbit
guinea
pig
dog
pig
mani
mammal
chodosh
et
al
seo
et
al
ocular
mucos
deliveri
peptid
epitop
herp
simplex
viru
glycoprotein
gd
mix
oligodeoxi
nucleotid
contain
unmethyl
cpg
motif
result
suggest
enhanc
local
system
immun
respons
multiinstil
gd
peptid
epitop
adjuv
nesburn
et
al
ocular
mucos
administr
iron
nanoparticl
glutam
acid
contain
dna
vaccin
herp
stromal
kerat
confer
protect
mucos
challeng
herp
simplex
viru
type
mice
hu
et
al
vagin
mucosa
portal
entri
mani
viral
bacteri
pathogen
vagin
rout
serv
potenti
site
drug
administr
local
system
absorpt
therapeut
import
molecul
protein
peptid
small
interf
rna
oligonucleotid
antigen
vaccin
hormon
hussain
ahsan
one
altern
site
system
deliveri
protein
drug
rel
high
permeabl
vagin
epithelium
passag
hepat
firstpass
metabol
larg
surfac
area
rich
blood
suppli
gupta
et
al
gordon
et
al
thermosensit
mucoadhes
vagin
vaccin
deliveri
system
also
test
local
system
antibodi
respons
hpv
viruslik
particl
park
et
al
vagin
deliveri
vaccin
associ
vagin
infect
could
better
altern
induc
immun
respons
genit
mucosa
capabl
control
entri
pathogen
noninvas
gene
deliveri
approach
could
abl
deliv
express
nake
plasmid
dna
tissuespecif
local
deliveri
skin
sever
advantag
needlefre
noninvas
gene
administr
limit
toxic
potenti
cell
receptorindepend
uptak
minim
dna
size
restrict
potenti
multipl
treatment
via
rel
uncompl
administr
modal
thu
improv
patient
complianc
topic
appli
formul
especi
nanosystem
shown
enter
skin
accumul
hair
follicl
diffus
via
dendrit
cell
drain
lymph
node
elicit
antigenspecif
humor
cellmedi
immun
nasir
number
method
develop
perform
noninvas
topic
gene
deliveri
includ
passiv
diffus
genet
materi
skin
patch
skin
well
activ
process
iontophoresi
sonophoresi
electropor
chemic
enhanc
diffus
mehierhumbert
guy
topic
vaccin
achiev
use
topic
applic
nake
dna
without
tape
strip
dnalipidbas
complex
liposom
niosom
transfersom
microemuls
cui
sloat
ethanolinfluorocarbonbas
microemuls
topic
deliveri
anthrax
protect
antigen
pa
proteinencod
dna
vaccin
pgpa
pgpaload
microemuls
significantli
enhanc
antipa
antibodi
respons
cui
sloat
similarli
dna
deliveri
novel
lipidbas
biphas
deliveri
system
signific
deliv
plasmid
dna
viabl
layer
skin
foldvari
et
al
plasmid
dnaencod
hepat
b
surfac
antigen
hbsag
load
cation
transfersom
also
util
topic
immun
result
reveal
dnaload
cation
transfersom
elicit
significantli
higher
antihbsag
antibodi
titer
cytokin
level
compar
nake
dna
also
observ
topic
applic
dnaload
cation
transfersom
elicit
compar
serum
antibodi
titer
endogen
cytokin
level
produc
intramuscular
recombin
hbsag
administr
mahor
et
al
size
polystyren
nanoparticl
studi
target
activ
compound
hair
follicl
may
result
better
penetr
higher
effici
compound
uptak
skin
resid
cell
studi
demonstr
nm
np
modifi
vaccinia
ankara
mva
express
greenfluoresc
protein
penetr
deepli
hair
follicl
uptak
apc
transport
drain
lymph
node
mahe
et
al
nanoengin
genet
vaccin
formul
develop
topic
immun
compris
emulsifi
wax
oil
phase
ctab
cation
surfact
mannan
dc
ligand
dioleoylphosphatidylethanolamin
endosomolyt
agent
cholesterol
pdnacoat
nanoparticl
especi
mannanco
pdnananoparticl
dope
shown
signific
immun
respons
igg
titer
nake
pdna
alon
cui
mumper
diffus
patch
tape
strip
techniqu
use
deliveri
small
da
larg
molecul
respect
liquid
jet
injector
approach
dna
vaccin
deliv
around
langerhan
cell
highspe
injector
chen
et
al
report
particlemedi
genegun
dna
immun
use
similar
mechan
devic
deliv
dna
vaccin
viabl
epidermi
chen
et
al
microneedl
array
set
needl
microscal
length
nanoscal
tip
coat
dna
accur
effici
safe
deliv
biomolecul
viabl
cell
epidermi
recent
tran
et
al
develop
uniqu
nanoliposom
ultrasoundmedi
devic
deliv
small
interf
rna
sirna
specif
target
melanocyt
tumor
present
skin
observ
decreas
earli
melanocyt
lesion
develop
skin
prevent
spread
cutan
metastas
melanoma
tran
et
al
result
suggest
skin
may
provid
appeal
noninvas
rout
deliveri
dna
vaccin
therapeut
gene
tabl
repres
posit
neg
aspect
variou
rout
administr
help
select
particular
rout
novel
vaccin
carrier
adjuv
vehicl
particlebas
deliveri
strategi
evalu
varieti
vaccin
includ
diseas
cancer
malaria
aid
hepat
etc
cellular
andor
mucos
immun
respons
desir
variou
immun
respons
gener
differ
adjuv
like
mpl
gener
respons
vlp
virosom
nondegrad
nanoparticl
liposom
gener
cellular
immun
respons
human
viral
vector
iscom
variou
nanoparticul
immunopotenti
antigen
deliveri
vehicl
shown
ctl
respons
desir
respons
achiev
use
combin
variou
adjuv
system
antibodi
produc
human
viralvector
vaccin
well
proteasom
given
clinic
trial
requir
vaccin
approv
often
long
difficult
furthermor
sinc
mani
vaccin
often
administ
healthi
individu
frequent
infant
critic
proven
safe
well
toler
nonhuman
primat
enter
human
trial
develop
novel
vaccin
deliveri
system
adjuv
aid
nanotechnolog
must
necessari
perceiv
potenti
problem
high
surfac
area
reactiv
abil
cross
biolog
membran
slow
biodegrad
materi
safeti
toler
approv
mani
challeng
must
met
new
class
vaccin
becom
avail
like
abil
stimul
humor
cellular
mucos
immun
respons
longer
durat
respons
easili
metabol
vaccin
compon
bodi
costeffect
product
lesser
risk
less
invas
approach
administr
vaccin
challeng
met
prevent
therapi
mani
previous
untreat
diseas
becom
increasingli
possibl
